Traumatic Brain Injury Market H1 2015 – Industry Analysis, Market Size, Growth, Trends Radiant Insights, Inc
Global Markets Direct’s, ‘Traumatic Brain Injury - Pipeline Review, H1 2015’, provides an overview of the Traumatic Brain Injury’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects. Browse Full Report With TOC @ http://www.radiantinsights.com/research/traumatic-brain-injury-pipeline-review-h1-2015 Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Global Markets Direct’s, ‘Traumatic Brain Injury - Pipeline Review, H1 2015’, provides an overview of the Traumatic Brain Injury’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects.
Browse Full Report With TOC @ http://www.radiantinsights.com/research/traumatic-brain-injury-pipeline-review-h1-2015
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Traumatic</strong> <strong>Brain</strong> <strong>Injury</strong> <strong>Market</strong> <strong>H1</strong> <strong>2015</strong> <strong>–</strong> <strong>Industry</strong> <strong>Analysis</strong>,<br />
<strong>Market</strong> <strong>Size</strong>, <strong>Growth</strong>, <strong>Trends</strong>: <strong>Radiant</strong> <strong>Insights</strong>, <strong>Inc</strong><br />
Summary<br />
Global <strong>Market</strong>s Direct’s, ‘<strong>Traumatic</strong> <strong>Brain</strong> <strong>Injury</strong> - Pipeline Review, <strong>H1</strong> <strong>2015</strong>’, provides an overview of<br />
the <strong>Traumatic</strong> <strong>Brain</strong> <strong>Injury</strong>’s therapeutic pipeline.<br />
This report provides comprehensive information on the therapeutic development for <strong>Traumatic</strong> <strong>Brain</strong><br />
<strong>Injury</strong>, complete with comparative analysis at various stages, therapeutics assessment by drug target,<br />
mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates,<br />
and featured news and press releases. It also reviews key players involved in the therapeutic development<br />
for <strong>Traumatic</strong> <strong>Brain</strong> <strong>Injury</strong> and special features on late-stage and discontinued projects.<br />
Browse Full Report With TOC @ http://www.radiantinsights.com/research/traumatic-braininjury-pipeline-review-h1-<strong>2015</strong><br />
Global <strong>Market</strong>s Direct’s report features investigational drugs from across globe covering over 20 therapy<br />
areas and nearly 3,000 indications. The report is built using data and information sourced from Global<br />
<strong>Market</strong>s Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations<br />
and featured press releases from company/university sites and industry-specific third party sources, put<br />
together by Global <strong>Market</strong>s Direct’s team. Drug profiles/records featured in the report undergoes periodic<br />
updation following a stringent set of processes that ensures that all the profiles are updated with the latest<br />
set of information. Additionally, processes including live news & deals tracking, browser based alert-box<br />
and clinical trials registries tracking ensure that the most recent developments are captured on a real time<br />
basis.<br />
The report enhances decision making capabilities and help to create effective counter strategies to gain<br />
competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce<br />
first-in-class and best-in-class products.<br />
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of<br />
data for the indicated disease.<br />
Scope<br />
- The report provides a snapshot of the global therapeutic landscape of <strong>Traumatic</strong> <strong>Brain</strong> <strong>Injury</strong><br />
- The report reviews key pipeline products under drug profile section which includes, product description,<br />
MoA and R&D brief, licensing and collaboration details & other developmental activities<br />
- The report reviews key players involved in the therapeutics development for <strong>Traumatic</strong> <strong>Brain</strong> <strong>Injury</strong> and<br />
enlists all their major and minor projects<br />
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the <strong>Traumatic</strong> <strong>Brain</strong> <strong>Injury</strong> products under development by companies and<br />
universities/research institutes based on information derived from company and industry-specific sources<br />
- Pipeline products coverage based on various stages of development ranging from pre-registration till<br />
discovery and undisclosed stages<br />
- A detailed assessment of monotherapy and combination therapy pipeline projects<br />
- Coverage of the <strong>Traumatic</strong> <strong>Brain</strong> <strong>Injury</strong> pipeline on the basis of target, MoA, route of administration and<br />
molecule type<br />
- Latest news and deals relating related to pipeline products<br />
Browse Full Report With TOC @ http://www.radiantinsights.com/research/traumatic-braininjury-pipeline-review-h1-<strong>2015</strong><br />
Reasons to buy<br />
- Provides strategically significant competitor information, analysis, and insights to formulate effective<br />
R&D development strategies<br />
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies<br />
to gain competitive advantage<br />
- Develop strategic initiatives by understanding the focus areas of leading companies<br />
- Identify and understand important and diverse types of therapeutics under development for <strong>Traumatic</strong><br />
<strong>Brain</strong> <strong>Injury</strong><br />
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline<br />
- Devise corrective measures for pipeline projects by understanding <strong>Traumatic</strong> <strong>Brain</strong> <strong>Injury</strong> pipeline depth<br />
and focus of Indication therapeutics<br />
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the<br />
most attractive projects to enhance and expand business potential and scope<br />
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that<br />
drove them from pipeline<br />
Table of Contents<br />
Table of Contents 2<br />
List of Tables 6<br />
List of Figures 8
Introduction 9<br />
Global <strong>Market</strong>s Direct Report Coverage 9<br />
<strong>Traumatic</strong> <strong>Brain</strong> <strong>Injury</strong> Overview 10<br />
Therapeutics Development 11<br />
Pipeline Products for <strong>Traumatic</strong> <strong>Brain</strong> <strong>Injury</strong> - Overview 11<br />
Pipeline Products for <strong>Traumatic</strong> <strong>Brain</strong> <strong>Injury</strong> - Comparative <strong>Analysis</strong> 12<br />
<strong>Traumatic</strong> <strong>Brain</strong> <strong>Injury</strong> - Therapeutics under Development by Companies 13<br />
<strong>Traumatic</strong> <strong>Brain</strong> <strong>Injury</strong> - Therapeutics under Investigation by Universities/Institutes 18<br />
<strong>Traumatic</strong> <strong>Brain</strong> <strong>Injury</strong> - Pipeline Products Glance 19<br />
Browse Full Report With TOC @ http://www.radiantinsights.com/research/traumatic-braininjury-pipeline-review-h1-<strong>2015</strong><br />
Late Stage Products 19<br />
Clinical Stage Products 20<br />
Early Stage Products 21<br />
Unknown Stage Products 22<br />
<strong>Traumatic</strong> <strong>Brain</strong> <strong>Injury</strong> - Products under Development by Companies 23<br />
<strong>Traumatic</strong> <strong>Brain</strong> <strong>Injury</strong> - Products under Investigation by Universities/Institutes 28<br />
<strong>Traumatic</strong> <strong>Brain</strong> <strong>Injury</strong> - Companies Involved in Therapeutics Development 29<br />
Adamas Pharmaceuticals, <strong>Inc</strong>. 29<br />
ALSP, <strong>Inc</strong>. 30<br />
Amarantus Bioscience Holdings, <strong>Inc</strong>. 31<br />
Athersys, <strong>Inc</strong>. 32<br />
BHR Pharma, LLC 33<br />
Cognosci, <strong>Inc</strong>. 34<br />
Concert Pharmaceuticals, <strong>Inc</strong>. 35<br />
Euroscreen S.A. 36
Grupo Ferrer Internacional, S.A. 37<br />
International Stem Cell Corporation 38<br />
Io Therapeutics, <strong>Inc</strong>. 39<br />
Ischemix 40<br />
Karyopharm Therapeutics, <strong>Inc</strong>. 41<br />
Kyorin Pharmaceutical Co., Ltd. 42<br />
Levolta Pharmaceuticals, <strong>Inc</strong>. 43<br />
Lixte Biotechnology Holdings, <strong>Inc</strong>. 44<br />
Lpath, <strong>Inc</strong>. 45<br />
MandalMed, <strong>Inc</strong>. 46<br />
Mapreg S.A.S. 47<br />
Browse Full Report With TOC @ http://www.radiantinsights.com/research/traumatic-braininjury-pipeline-review-h1-<strong>2015</strong><br />
Mnemosyne Pharmaceuticals, <strong>Inc</strong>. 48<br />
NeoStem, <strong>Inc</strong>. 49<br />
Neuralstem, <strong>Inc</strong>. 50<br />
Neuren Pharmaceuticals Limited 51<br />
NeuroHealing Pharmaceuticals <strong>Inc</strong>. 52<br />
NeuroNascent, <strong>Inc</strong>. 53<br />
Neuronax SAS 54<br />
NeuroVive Pharmaceutical AB 55<br />
Omeros Corporation 56<br />
PharmatrophiX, <strong>Inc</strong>. 57<br />
Phylogica Limited 58<br />
Prevacus, <strong>Inc</strong>. 59<br />
PsychoGenics, <strong>Inc</strong>. 60
QR Pharma, <strong>Inc</strong>. 61<br />
RAPID Pharmaceuticals AG 62<br />
RegeneRx Biopharmaceuticals, <strong>Inc</strong>. 63<br />
Remedy Pharmaceuticals, <strong>Inc</strong>. 64<br />
Sage Therapeutics 65<br />
SanBio, <strong>Inc</strong>. 66<br />
STATegics, <strong>Inc</strong>. 67<br />
SynZyme Technologies, LLC 68<br />
Tetra Discovery Partners LLC 69<br />
vasopharm GmbH 70<br />
Browse Full Report With TOC @ http://www.radiantinsights.com/research/traumatic-braininjury-pipeline-review-h1-<strong>2015</strong><br />
VG Life Sciences, <strong>Inc</strong>. 71<br />
<strong>Traumatic</strong> <strong>Brain</strong> <strong>Injury</strong> - Therapeutics Assessment 72<br />
Assessment by Monotherapy Products 72<br />
Assessment by Combination Products 73<br />
Assessment by Target 74<br />
Assessment by Mechanism of Action 77<br />
Assessment by Route of Administration 80<br />
Assessment by Molecule Type 82<br />
Drug Profiles 84<br />
2-DG - Drug Profile 84<br />
ALP-496 - Drug Profile 86<br />
amantadine hydrochloride ER - Drug Profile 88<br />
AMR-001 - Drug Profile 90<br />
AMRS-001 - Drug Profile 92
apomorphine hydrochloride - Drug Profile 94<br />
AVL-8168 - Drug Profile 96<br />
BHR-310 - Drug Profile 97<br />
C-10068 - Drug Profile 98<br />
Cell Therapy to Activate hNT-3 for Spinal Cord and <strong>Traumatic</strong> <strong>Brain</strong> <strong>Injury</strong> - Drug Profile 99<br />
CHEC-7 - Drug Profile 100<br />
CHEC-9 - Drug Profile 101<br />
CMX-2043 - Drug Profile 103<br />
CNB-001 - Drug Profile 105<br />
COG-1410 - Drug Profile 107<br />
Browse Full Report With TOC @ http://www.radiantinsights.com/research/traumatic-braininjury-pipeline-review-h1-<strong>2015</strong><br />
cyclosporine - Drug Profile 109<br />
dexamethasone acetate + melatonin - Drug Profile 112<br />
EPO-Variant - Drug Profile 113<br />
ESN-502 - Drug Profile 114<br />
felbamate - Drug Profile 115<br />
FIB-117 - Drug Profile 116<br />
glyburide - Drug Profile 117<br />
HBN-1 - Drug Profile 119<br />
HBN-2 - Drug Profile 120<br />
ibudilast - Drug Profile 121<br />
ICCN-100 - Drug Profile 123<br />
IRX-4204 - Drug Profile 124<br />
KPT-350 - Drug Profile 126<br />
LB-201 - Drug Profile 127
LB-205 - Drug Profile 128<br />
LM11A-31 - Drug Profile 129<br />
Lpathomab - Drug Profile 130<br />
MAP-4343 - Drug Profile 131<br />
MultiStem - Drug Profile 132<br />
ND-478 - Drug Profile 135<br />
NNI-370 - Drug Profile 136<br />
NNZ-2591 - Drug Profile 137<br />
Browse Full Report With TOC @ http://www.radiantinsights.com/research/traumatic-braininjury-pipeline-review-h1-<strong>2015</strong><br />
NSI-189 - Drug Profile 139<br />
NSI-566 - Drug Profile 140<br />
NVP-019 - Drug Profile 142<br />
NVX-428 - Drug Profile 143<br />
NX-210 - Drug Profile 144<br />
Peptides for Central Nervous System and Musculoskeletal Disorders - Drug Profile 145<br />
PGI-02776 - Drug Profile 146<br />
Posiphen - Drug Profile 148<br />
progesterone - Drug Profile 150<br />
PRV-002 - Drug Profile 151<br />
PYC-35 - Drug Profile 152<br />
PYC-36 - Drug Profile 153<br />
PYC-38 - Drug Profile 154<br />
PYC-98 - Drug Profile 155<br />
R-503 - Drug Profile 156<br />
RAP-701 - Drug Profile 158
RGN-352 - Drug Profile 159<br />
SAGE-547 - Drug Profile 161<br />
SB-623 - Drug Profile 163<br />
Small Molecule to Activate Epsilon PKC for <strong>Traumatic</strong> <strong>Brain</strong> <strong>Injury</strong> - Drug Profile 164<br />
Small Molecule to Antagonize GPR17 for Central Nervous System Disorders - Drug Profile 165<br />
Small Molecule to Antagonize NMDA2A for Central Nervous System Disorder - Drug Profile 166<br />
Small Molecule to Inhibit Amyloid Beta Peptide for <strong>Traumatic</strong> <strong>Brain</strong> <strong>Injury</strong> and Alzheimer’s Disease -<br />
Drug Profile 167<br />
Browse Full Report With TOC @ http://www.radiantinsights.com/research/traumatic-braininjury-pipeline-review-h1-<strong>2015</strong><br />
Small Molecule to Inhibit PDE4 for <strong>Traumatic</strong> <strong>Brain</strong> <strong>Injury</strong> - Drug Profile 168<br />
Small Molecules for Stroke and <strong>Traumatic</strong> <strong>Brain</strong> <strong>Injury</strong> - Drug Profile 169<br />
Small Molecules to Activate P2Y Receptor for Stroke and <strong>Traumatic</strong> <strong>Brain</strong> <strong>Injury</strong> - Drug Profile 170<br />
Small Molecules to Agonize TrkB for Ophthalmology and Central Nervous System - Drug Profile 171<br />
Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile 172<br />
Small Molecules to Inhibit PBR for <strong>Traumatic</strong> <strong>Brain</strong> <strong>Injury</strong> and Neurodegenerative Diseases - Drug<br />
Profile 173<br />
Stem Cell Therapy for Parkinson’s Disease, <strong>Traumatic</strong> <strong>Brain</strong> <strong>Injury</strong> and Stroke - Drug Profile 174<br />
Stem Cell Therapy for <strong>Traumatic</strong> Spinal Cord <strong>Injury</strong> and <strong>Brain</strong> <strong>Injury</strong> - Drug Profile 176<br />
STSE-15 - Drug Profile 177<br />
TBI-121 - Drug Profile 178<br />
TBI-122 - Drug Profile 179<br />
TBI-123 - Drug Profile 180<br />
trofinetide - Drug Profile 181<br />
UH-0113 - Drug Profile 183<br />
UH-0213 - Drug Profile 184<br />
VAS-203 - Drug Profile 185
VG-1177 - Drug Profile 187<br />
VitalHeme - Drug Profile 189<br />
VOLT-02 - Drug Profile 191<br />
<strong>Traumatic</strong> <strong>Brain</strong> <strong>Injury</strong> - Recent Pipeline Updates 192<br />
<strong>Traumatic</strong> <strong>Brain</strong> <strong>Injury</strong> - Dormant Projects 245<br />
<strong>Traumatic</strong> <strong>Brain</strong> <strong>Injury</strong> - Discontinued Products 249<br />
<strong>Traumatic</strong> <strong>Brain</strong> <strong>Injury</strong> - Product Development Milestones 250<br />
Featured News & Press Releases 250<br />
Browse Full Report With TOC @ http://www.radiantinsights.com/research/traumatic-braininjury-pipeline-review-h1-<strong>2015</strong><br />
About <strong>Radiant</strong> <strong>Insights</strong><br />
<strong>Radiant</strong> <strong>Insights</strong> is a platform for companies looking to meet their market research and business<br />
intelligence requirements. We assist and facilitate organizations and individuals procure market research<br />
reports, helping them in the decision making process. We have a comprehensive collection of reports,<br />
covering over 40 key industries and a host of micro markets. In addition to over extensive database of<br />
reports, our experienced research coordinators also offer a host of ancillary services such as, research<br />
partnerships/ tie-ups and customized research solutions.<br />
For More Information, Visit <strong>Radiant</strong> <strong>Insights</strong><br />
Contact:<br />
Michelle Thoras<br />
Corporate Sales Specialist, USA<br />
<strong>Radiant</strong> <strong>Insights</strong>, <strong>Inc</strong><br />
Phone: 1-415-349-0054<br />
Toll Free: 1-888-202-9519<br />
Email: sales@radiantinsights.com<br />
Blog URL: http://chemicalmaterialsmarket.blogspot.in/
Change language